# US Type 2 Diabetes Mellitus Treatment Market

> US Type 2 Diabetes Mellitus Treatment Market Research Report: By Treatment (Drug Class, Devices) and By End User (Hospitals, Clinics, Diagnostic Centers, Drug Stores, Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.45%
- **2024:** $ 3,960.6 Million
- **2025:** $ 4,334.88 Million
- **2035:** $ 10,693.83 Million
- **Key Players:** Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Merck & Co. (US), AstraZeneca (GB), Johnson & Johnson (US), Eli Lilly and Company (US), AbbVie (US)

**Report ID:** MRFR/Pharma/17499-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-type-2-diabetes-mellitus-treatment-market-19045

---

## Market Summary

## **US Type 2 Diabetes Mellitus Treatment Market Overview**

As per MRFR analysis, the US Type 2 Diabetes Mellitus Treatment Market Size was estimated at 3.89 (USD Billion) in 2023. The US Type 2 Diabetes Mellitus Treatment Market Industry is expected to grow from 4.2(USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The US Type 2 Diabetes Mellitus Treatment Market CAGR (growth rate) is expected to be around 10.423% during the forecast period (2025 - 2035).

### **Key US Type 2 Diabetes Mellitus Treatment Market Trends Highlighted**

In the US Type 2 Diabetes Mellitus Treatment Market, there are several significant market drivers shaping the landscape. The rising prevalence of Type 2 diabetes among the US population, driven by factors such as obesity, sedentary lifestyles, and an aging demographic, is a key factor pushing the demand for effective treatments. Increased awareness about diabetes management and preventive measures has also led to a greater emphasis on early intervention and treatment protocols across healthcare providers.

Opportunities in this market include the growing adoption of telehealth services and digital health solutions, which facilitate remote monitoring and personalized treatment plans for diabetes patients.Innovations in drug delivery systems, like insulin pens and continuous glucose monitors, are also creating new avenues for patient compliance and engagement. Furthermore, with ongoing research into novel therapeutics, such as GLP-1 receptor agonists and SGLT2 inhibitors, there is potential for significant advancements in treatment efficacy and safety.

Trends in recent times indicate a shift toward patient-centered care approaches, emphasizing the importance of tailored treatment plans based on individual patient needs. The integration of lifestyle modification programs alongside pharmacological treatments is becoming more common, reflecting a holistic approach to diabetes management.Additionally, there is increasing collaboration among pharmaceutical companies, tech firms, and healthcare providers to develop comprehensive solutions addressing both medical and lifestyle components of diabetes care. The regulatory environment in the US is supportive, with initiatives aimed at promoting innovative therapies and improving patient access to medications and treatment resources.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Type 2 Diabetes Mellitus Treatment Market Drivers**

### **Rising Prevalence of Type 2 Diabetes in the US**

The increasing incidence of Type 2 Diabetes Mellitus in the United States is a significant driver for the US Type 2 Diabetes Mellitus Treatment Market Industry. According to the Centers for Disease Control and Prevention (CDC), over 34 million Americans suffer from diabetes, with approximately 90-95% of those cases being Type 2 diabetes. This represents about one in ten US adults, which indicates a substantial and growing patient population requiring treatment options.

Additionally, the CDC projects that the prevalence of diabetes will increase significantly over the next decade due to rising obesity rates and sedentary lifestyles among the American population. With organizations like the American Diabetes Association (ADA) raising awareness and advocating for better treatment solutions, the push for effective diabetes management tools will stimulate market growth significantly in the US Type 2 Diabetes Mellitus Treatment Market.

### **Advancements in Diabetes Management Technology**

The rapid advancement in diabetes management technologies is driving the growth of the US Type 2 Diabetes Mellitus Treatment Market. Innovations such as continuous glucose monitoring systems and automated insulin delivery systems have gained traction. According to the Food and Drug Administration (FDA), over the past year, there has been a notable increase in the number of approved diabetes management devices, resulting in a wider array of treatment options for patients.

These technological advancements not only provide better diabetes management but also enhance patient compliance and overall health outcomes. Organizations like Medtronic and Abbott Laboratories are leading the charge in this technology space, making significant contributions to improving the quality of care in the US.

### **Increased Awareness and Education about Diabetes**

Increasing awareness and education initiatives related to diabetes management are contributing to the growth of the US Type 2 Diabetes Mellitus Treatment Market. The American Diabetes Association has initiated various campaigns aimed at educating individuals about the risks and prevention methods associated with Type 2 diabetes. Statistically, health education programs have shown to improve patient outcomes significantly, with the National Institute of Diabetes and Digestive and Kidney Diseases reporting that educated patients are 1.5 times more likely to engage proactively in their health management.

This growing awareness translates to higher demand for treatments and management solutions within the market.

### **Government Support and Policy Changes for Diabetes Care**

Government policies and support are proving to be substantial drivers of the US Type 2 Diabetes Mellitus Treatment Market. The Affordable Care Act (ACA) has enabled better insurance coverage for diabetes screening and prevention services, creating a wider access to healthcare resources for patients. According to the US Department of Health and Human Services, since the implementation of ACA, millions of Americans have gained access to critical diabetes prevention programs.

This shift in policy has led to increased screening, detection, and treatment of Type 2 diabetes, thus fostering market growth. Moreover, the government is investing in diabetes research, providing funding to organizations which enhances Research and Development of new treatment options, positively influencing the future landscape of the US Type 2 Diabetes Mellitus Treatment Market.

## **US Type 2 Diabetes Mellitus Treatment Market Segment Insights**

### **Type 2 Diabetes Mellitus Treatment Market Treatment Insights**

The Treatment segment of the US Type 2 Diabetes Mellitus Treatment Market is a pivotal component, reflecting the growing challenges posed by this chronic illness. This segment encapsulates diverse therapeutic approaches, with Drug Class and Devices playing crucial roles in managing Type 2 diabetes. The Drug Class category typically encompasses various medications designed to regulate blood glucose levels and improve overall metabolic function, which are integral as many individuals diagnosed with Type 2 diabetes require pharmacological support to maintain their health and prevent complications.

The significance of this category is underscored by the expanding array of innovative drugs entering the market, which include oral medications and injectable therapies that address distinct patient needs and preferences.Devices, another essential aspect of the Treatment segment, have gained substantial traction among patients and healthcare providers alike. Continuous glucose monitors and insulin delivery systems, for example, represent significant advancements in diabetes care technology.

These devices offer improved accuracy and convenience, which is critical in fostering better adherence to treatment regimens and enhancing patient quality of life. As healthcare technology continues to evolve, these devices are becoming increasingly integrated into daily management routines, thus reflecting a shift toward more personalized and patient-centric approaches to diabetes management.The market dynamics are influenced by several factors, including the rising prevalence of Type 2 diabetes in the United States, which is linked to increasing obesity rates and sedentary lifestyles.

Furthermore, ongoing Research and Development initiatives have the potential to introduce next-generation treatment options that could reshape both the Drug Class and Devices categories, catering to a diverse patient population with varying treatment requirements. Additionally, market trends indicate a growing awareness among patients about the importance of early intervention and diligent disease management, leading to heightened demand for both medications and monitoring devices. Challenges, such as the high cost of some newer medications and devices, remain pertinent. However, opportunities also abound, particularly in the form of advancements in digital health solutions aimed at supporting diabetes management.

These developments highlight the expansive nature of the Treatment segment, reinforcing its critical role in addressing the evolving landscape of Type 2 Diabetes Mellitus care in the US.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Type 2 Diabetes Mellitus Treatment Market End User Insights**

The End User segment of the US Type 2 Diabetes Mellitus Treatment Market shows diverse pathways to address the needs of a growing population suffering from diabetes. Hospitals and Clinics play a pivotal role, offering comprehensive treatment plans and patient management strategies that are critical for effective diabetes care. Diagnostic Centers contribute significantly by providing essential testing and monitoring services, thus enabling early detection and management of the disease.

Pharmacies and Drug Stores serve as major points of medication distribution, ensuring patients have access to pharmaceuticals necessary for their treatment regimen.The variation in End User dynamics reflects an increasing demand for tailored treatment options, spurred by the continuous rise in obesity rates and sedentary lifestyles across the United States. Additionally, convenience and accessibility remain vital, as patients often seek care and medications close to their homes.

The importance of this segment is underscored by the need for integrated health management systems that allow for improved outcomes in managing Type 2 Diabetes Mellitus. Overall, this segment's growth trajectory is propelled by an expanding patient base, innovative treatment modalities, and a heightened emphasis on preventive healthcare.

## **US Type 2 Diabetes Mellitus Treatment Market Key Players and Competitive Insights**

The US Type 2 Diabetes Mellitus Treatment Market represents a significant segment of the broader healthcare industry, owing to the high prevalence of diabetes in the region. Competitive dynamics in this market are driven by a range of factors, including innovative treatment options, an increasing emphasis on patient-centric care, and a robust pipeline of drugs. As research and development efforts intensify, companies are focusing on personalized medicine and exploring new therapeutic targets to enhance treatment efficacy.

In this environment, companies are not only vying for market share through novel therapies but also are investing in partnerships that could propel their products to the forefront of diabetes management. Regulatory approvals and market access strategies play a pivotal role in determining success, as firms need to navigate complex healthcare systems and reimbursement landscapes.

Merck and Co has established a strong presence in the US Type 2 Diabetes Mellitus Treatment Market through its innovative therapies and commitment to diabetes research. The company's strengths lie in its robust product portfolio, which includes medications that address various aspects of diabetes management. Merck emphasizes the integration of its treatment options with patient care programs, enhancing patient adherence and outcomes.

Their strategic partnerships with healthcare providers and organizations strengthen their market position, allowing them to leverage data-driven approaches that improve treatment pathways. Merck's ongoing commitment to clinical research continues to bolster its reputation as a leader in the field, paving the way for new solutions whilst solidifying its existing market offerings.

AstraZeneca also holds a significant position in the US Type 2 Diabetes Mellitus Treatment Market, with a focus on delivering innovative therapies that address the evolving needs of diabetic patients. The company is known for its cardiovascular and metabolic medications, which target not only diabetes management but also associated cardiovascular risks. AstraZeneca has made strategic advancements through mergers and acquisitions, which have expanded its therapeutic portfolio and enhanced its operational capabilities.

Key products from AstraZeneca in the diabetes segment include medications that have shown strong efficacy in clinical trials and are well-positioned within the competitive landscape. The company continues to invest in research to further its advancements in diabetes care, fostering collaborations with healthcare stakeholders to improve patient access and health outcomes in the US market.

### **Key Companies in the US Type 2 Diabetes Mellitus Treatment Market Include**

## **US Type 2 Diabetes Mellitus Treatment Market Industry Developments**

Recent developments in the US Type 2 Diabetes Mellitus Treatment Market include several notable advancements and initiatives among key players. In September 2023, Eli Lilly announced a new partnership focusing on innovative therapies, enhancing their portfolio amid rising competition. Meanwhile, in August 2023, Novo Nordisk received approval for its new injectable medication, aimed at improving glycemic control, reflecting regulatory progress in this sector.

AstraZeneca revealed in July 2023 a comprehensive trial demonstrating the effectiveness of its SGLT2 inhibitor, which is gaining traction in treatment regimens.Furthermore, discussions surrounding mergers and acquisitions are heating up, particularly with Takeda Pharmaceutical and Boehringer Ingelheim eyeing strategic alliances to bolster their market presence.

The valuation of companies in the market has seen an upward trend, fueled by increasing investment in Research and Development and the demand for advanced therapies, which could potentially reshape treatment paradigms. In recent years, the market dynamics shifted significantly, particularly with the surge in telehealth solutions for diabetes management during the pandemic, notably impacting patient access and treatment strategies. Key stakeholders continue to adapt to these changes, aiming to optimize care for the growing population affected by Type 2 Diabetes in the US.

## **US Type 2 Diabetes Mellitus Treatment Market Segmentation Insights**

### **Type 2 Diabetes Mellitus Treatment Market Treatment Outlook**

### **Type 2 Diabetes Mellitus Treatment Market End User Outlook**

## Market Drivers

### Rising Healthcare Expenditure

The increasing healthcare expenditure in the US is a notable driver for the type 2-diabetes-mellitus-treatment market. In 2020, national health spending reached approximately $4 trillion, with a significant portion allocated to chronic disease management, including diabetes. This trend suggests a growing recognition of the need for effective treatment solutions. As healthcare costs continue to rise, there is a push for innovative therapies that can reduce long-term complications associated with diabetes. The type 2-diabetes-mellitus-treatment market is likely to see increased investment in research and development, leading to the introduction of new treatment modalities. This financial commitment may enhance patient access to necessary therapies, further propelling market growth.

### Growing Awareness and Education

Increased awareness and education regarding type 2 diabetes are driving the treatment market in the US. Public health campaigns and educational initiatives by organizations such as the American Diabetes Association have significantly improved understanding of diabetes management. As individuals become more informed about the risks associated with untreated diabetes, there is a corresponding rise in demand for effective treatment options. The type 2-diabetes-mellitus-treatment market is likely to benefit from this trend, as patients actively seek out therapies that can help manage their condition. Furthermore, healthcare providers are increasingly focusing on patient education as a means to enhance treatment adherence, which may further stimulate market growth.

### Increasing Prevalence of Obesity

The rising prevalence of obesity in the US is a critical driver for the type 2-diabetes-mellitus-treatment market. According to the Centers for Disease Control and Prevention (CDC), approximately 42.4% of adults in the US were classified as obese in 2017-2018. This alarming trend correlates with a higher incidence of type 2 diabetes, as excess body weight is a significant risk factor. The type 2-diabetes-mellitus-treatment market is likely to expand as healthcare providers seek effective interventions for this growing population. Furthermore, the economic burden associated with obesity-related health conditions is substantial, with estimated costs exceeding $147 billion annually. As awareness of obesity's impact on diabetes increases, demand for treatment options is expected to rise, driving market growth.

### Advancements in Medical Technology

Technological advancements in medical devices and monitoring systems are transforming the type 2-diabetes-mellitus-treatment market. Innovations such as continuous glucose monitors (CGMs) and insulin delivery systems enhance patient management and adherence to treatment regimens. The integration of mobile health applications allows for real-time data tracking, which can lead to improved outcomes. The market for diabetes management devices is projected to reach $24 billion by 2026, indicating a robust growth trajectory. These advancements not only empower patients but also facilitate better communication between healthcare providers and patients, potentially leading to more personalized treatment plans. As technology continues to evolve, it is likely to play a pivotal role in shaping the future of the type 2-diabetes-mellitus-treatment market.

### Regulatory Support for New Treatments

Regulatory support for the approval of new diabetes treatments is a crucial driver for the type 2-diabetes-mellitus-treatment market. The US Food and Drug Administration (FDA) has streamlined the approval process for innovative therapies, encouraging pharmaceutical companies to invest in research and development. This regulatory environment fosters the introduction of novel medications and treatment options, which can significantly impact patient outcomes. The type 2-diabetes-mellitus-treatment market is likely to benefit from this supportive framework, as it enables quicker access to effective therapies. As new treatments enter the market, competition may increase, potentially leading to more affordable options for patients and healthcare providers.

## Future Outlook

The [Type 2 Diabetes Mellitus Treatment Market](https://www.marketresearchfuture.com/reports/type-2-diabetes-mellitus-treatment-market-5669) is projected to grow at a 9.45% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence, and enhanced patient awareness.

**New opportunities:**

- Development of personalized medication management platforms Expansion of telehealth services for diabetes care Investment in AI-driven predictive analytics for treatment optimization

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms.

## Segment Insights

### By Treatment: Drug Class (Largest) vs. Devices (Fastest-Growing)

In the US type 2-diabetes-mellitus-treatment market, the Drug Class segment holds a significant share, showcasing the traditional reliance on pharmaceuticals for managing diabetes. Medications such as metformin and newer drug classes are prominently featured, reflecting the established preferences among healthcare providers and patients alike. In contrast, Devices, including continuous glucose monitors and insulin pumps, have been gaining traction, driven by technological advancements and growing patient awareness.

The growth trend in this market is characterized by an increasing push towards personalized medicine and technology integration. The rising prevalence of type 2 diabetes is prompting investments in innovative treatments, especially in the Devices category, which is seen as the fastest-growing segment. This shift is influenced by factors such as improved patient engagement, the demand for better monitoring solutions, and the push for better health outcomes.

Drug Class (Dominant) vs. Devices (Emerging)

The Drug Class segment remains dominant within the US type 2-diabetes-mellitus-treatment market, characterized by a wide range of medications that effectively manage blood glucose levels. Traditional treatments like metformin continue to be staples, while newer classes enhance options for patients, particularly those with complications. On the other hand, the Devices segment is emerging rapidly, driven by innovations such as smart insulin pens and integrated mobile applications. These devices cater to the tech-savvy patient population, offering real-time data and personalized management, which is crucial for improving adherence and outcomes in diabetes care.

### By Drug Class: Insulin (Largest) vs. SGLT-2 Inhibitors (Fastest-Growing)

In the US type 2-diabetes-mellitus-treatment market, the drug class segment is characterized by a varied distribution of market share among its constituents. Insulin continues to dominate, commanding the largest share due to its established efficacy and widespread use in diabetic management. Other notable classes include Sensitizers and Secretagogues, which hold significant market shares, while Peptide Analogs and Alpha-Glucosidase Inhibitors represent smaller portions, reflecting their specific therapeutic roles.

Growth trends indicate a paradigm shift, especially with SGLT-2 Inhibitors experiencing the fastest growth. Factors contributing to this trend include increasing awareness of cardiovascular benefits associated with this class, alongside rising diabetic populations. Innovations and clinical endorsements are driving demand, making SGLT-2 Inhibitors increasingly popular among healthcare professionals and patients alike, positioning them for robust future gains.

Insulin (Dominant) vs. SGLT-2 Inhibitors (Emerging)

Insulin remains the dominant drug class in the US type 2-diabetes-mellitus-treatment market, reflecting decades of clinical validation and patient familiarity. It is often the first-line therapy in diabetes management, particularly for those with more severe cases. On the other hand, SGLT-2 Inhibitors are emerging rapidly, thanks to their dual benefit of glycemic control and cardioprotective properties. While Insulin is crucial for blood sugar regulation, SGLT-2 Inhibitors attract attention due to favorable safety profiles and positive outcomes in reducing complications associated with diabetes. This contrast highlights an evolving treatment landscape where innovative therapies are increasingly complementing traditional approaches.

### By Devices: Blood Glucose Monitoring Devices (Largest) vs. Insulin Delivery Devices (Fastest-Growing)

In the US type 2-diabetes-mellitus-treatment market, Blood Glucose Monitoring Devices hold a significant market share, primarily due to their essential role in diabetes management. These devices are widely adopted by patients to monitor their glucose levels regularly, leading to effective disease management and minimizing complications. Conversely, Insulin Delivery Devices are emerging rapidly, driven by technological advancements and a growing focus on personalized medicine solutions for diabetes management.

The growth trends in this segment are influenced by the increasing prevalence of type 2 diabetes and the rising demand for more efficient management tools. The FDA's favorable regulatory environment has also spurred innovations, particularly in insulin delivery mechanisms, making them more user-friendly and accurate. This dual growth scenario indicates a vibrant market where both segments are expanding to cater to diverse patient needs.

Monitoring Devices: Blood Glucose (Dominant) vs. Insulin Delivery (Emerging)

Blood Glucose Monitoring Devices are at the forefront of the US type 2-diabetes-mellitus-treatment market due to their critical role in helping patients manage their condition effectively. These devices allow for frequent and accurate glucose level monitoring, which is essential in preventing the complications associated with diabetes. With a large established user base, these devices are well integrated into the daily routines of patients, which reinforces their dominance in the market. On the other hand, Insulin Delivery Devices represent an emerging segment embracing cutting-edge technology such as smart pumps and pens that enhance the convenience and precision of insulin administration. Their rapid adoption is propelled by increasing patient awareness and the need for advanced therapy options, thus creating new opportunities for growth in this sector.

### By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the US type 2-diabetes-mellitus-treatment market, the distribution of market share among the end user segments is notably diverse. Hospitals account for the largest share, driven by their comprehensive treatment facilities and ability to manage complex cases. Clinics also represent a significant portion of the market, although they are growing rapidly due to increased accessibility and the rise of outpatient care models that prioritize convenience for patients.

The growth trends in this segment are primarily influenced by the rising incidence of type 2 diabetes, which in turn propels demand for various treatment options. Moreover, the increasing focus on preventive healthcare and the integration of technology in treatment protocols are remarkable growth drivers. As healthcare providers adapt, both hospitals and clinics are positioning themselves to capture greater market shares in this evolving landscape.

Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals remain the dominant end user segment in the US type 2-diabetes-mellitus-treatment market, characterized by their extensive resources and ability to offer multidisciplinary treatment approaches. They often provide a full spectrum of care, including inpatient services, specialized education programs, and access to the latest treatment innovations. Conversely, clinics are emerging as vital players by offering accessible and patient-centered services that appeal to a growing population looking for immediate care without the need for hospitalization. The flexibility of clinics in scheduling appointments and providing personalized care is addressing the needs of many patients, thus fostering their growth. As both segments evolve, cooperation and competition will define their roles in the overall market dynamics.

## Competitive Benchmarking

The type 2-diabetes-mellitus-treatment market in the US is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing emphasis on innovative treatment solutions. Major players such as Novo Nordisk (DK), Eli Lilly and Company (US), and Merck & Co. (US) are strategically positioned to leverage their extensive research and development capabilities. Novo Nordisk (DK) focuses on continuous innovation in insulin therapies, while Eli Lilly and Company (US) emphasizes a diversified portfolio that includes both insulin and non-insulin therapies. Merck & Co. (US) is enhancing its market presence through strategic partnerships and collaborations, which collectively shape a competitive environment that is increasingly focused on patient-centric solutions and technological advancements.Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure appears moderately fragmented, with several key players holding substantial market shares. This fragmentation allows for a variety of treatment options, fostering competition that drives innovation and improves patient outcomes. The collective influence of these major companies is significant, as they not only compete on product efficacy but also on service delivery and patient engagement strategies.
In October Eli Lilly and Company (US) announced a partnership with a leading telehealth provider to enhance remote patient monitoring for diabetes management. This strategic move is likely to improve patient adherence to treatment regimens and provide real-time data to healthcare providers, thereby enhancing overall treatment outcomes. Such initiatives reflect a growing trend towards integrating digital health solutions into traditional treatment paradigms, which may redefine patient engagement in the coming years.
In September Merck & Co. (US) launched a new diabetes management app designed to support patients in tracking their glucose levels and medication adherence. This app not only serves as a tool for patients but also collects valuable data that can inform future product development and marketing strategies. The introduction of such digital tools indicates a shift towards a more holistic approach to diabetes care, where technology plays a crucial role in patient management.
In August Novo Nordisk (DK) expanded its manufacturing capabilities in the US to meet the rising demand for its GLP-1 receptor agonists. This expansion is strategically important as it positions the company to respond more swiftly to market needs and enhances its supply chain reliability. By increasing local production, Novo Nordisk (DK) aims to reduce lead times and improve access to its innovative therapies, which could strengthen its competitive edge in the market.
As of November current trends in the type 2-diabetes-mellitus-treatment market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in enhancing their technological capabilities. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technology integration, and supply chain reliability, reflecting a broader shift towards value-based care in the healthcare sector.

## Recent News & Developments

Recent developments in the US Type 2 Diabetes Mellitus Treatment Market include several notable advancements and initiatives among key players. In September 2023, Eli Lilly announced a new partnership focusing on innovative therapies, enhancing their portfolio amid rising competition. Meanwhile, in August 2023, Novo Nordisk received approval for its new injectable medication, aimed at improving glycemic control, reflecting regulatory progress in this sector.

AstraZeneca revealed in July 2023 a comprehensive trial demonstrating the effectiveness of its SGLT2 inhibitor, which is gaining traction in treatment regimens.Furthermore, discussions surrounding mergers and acquisitions are heating up, particularly with Takeda Pharmaceutical and Boehringer Ingelheim eyeing strategic alliances to bolster their market presence.

The valuation of companies in the market has seen an upward trend, fueled by increasing investment in Research and Development and the demand for advanced therapies, which could potentially reshape treatment paradigms. In recent years, the market dynamics shifted significantly, particularly with the surge in telehealth solutions for diabetes management during the pandemic, notably impacting patient access and treatment strategies. Key stakeholders continue to adapt to these changes, aiming to optimize care for the growing population affected by Type 2 Diabetes in the US.

## Report Scope

| MARKET SIZE 2024 | 3960.6(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 4334.88(USD Million) |
| MARKET SIZE 2035 | 10693.83(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.45% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Merck & Co. (US), AstraZeneca (GB), Johnson & Johnson (US), Eli Lilly and Company (US), AbbVie (US) |
| Segments Covered | Treatment, Drug Class, Devices, End User |
| Key Market Opportunities | Integration of digital health solutions enhances patient engagement in the type 2-diabetes-mellitus-treatment market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the type 2-diabetes-mellitus-treatment market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What is the current valuation of the US type 2-diabetes-mellitus-treatment market as of 2024?**
A: The market valuation was $3960.6 Million in 2024.

**Q: What is the projected market valuation for the US type 2-diabetes-mellitus-treatment market in 2035?**
A: The projected valuation for 2035 is $10693.83 Million.

**Q: What is the expected CAGR for the US type 2-diabetes-mellitus-treatment market during the forecast period 2025 - 2035?**
A: The expected CAGR during this period is 9.45%.

**Q: Which companies are the key players in the US type 2-diabetes-mellitus-treatment market?**
A: Key players include Novo Nordisk, Sanofi, Boehringer Ingelheim, Merck & Co., AstraZeneca, Johnson & Johnson, Eli Lilly and Company, and AbbVie.

**Q: What are the main segments of the US type 2-diabetes-mellitus-treatment market?**
A: The main segments include Treatment, Drug Class, Devices, and End User.

**Q: What was the valuation of the Drug Class segment in 2024?**
A: The Drug Class segment had a valuation of $792.12 Million to $2100 Million.

**Q: How much did the Blood Glucose Monitoring Devices segment generate in 2024?**
A: The Blood Glucose Monitoring Devices segment generated $1580.2 Million in 2024.

**Q: What is the projected growth for Insulin Delivery Devices by 2035?**
A: The Insulin Delivery Devices segment is projected to grow from $2379.4 Million to $6493.83 Million by 2035.

**Q: What is the expected performance of the Devices segment in the US type 2-diabetes-mellitus-treatment market?**
A: The Devices segment is expected to grow from $1460.6 Million to $4193.83 Million during the forecast period.

**Q: Which end users are expected to drive growth in the US type 2-diabetes-mellitus-treatment market?**
A: End users include Hospitals, Clinics, Diagnostic Centers, Drug Stores, and Pharmacies, with varying valuations.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-type-2-diabetes-mellitus-treatment-market-19045*